Luk, Andrea O. Y. http://orcid.org/0000-0002-5244-6069
Zee, Benny C. Y.
Chong, Marc
Ozaki, Risa
Rausch, Carl W.
Chan, Michael H. M.
Ma, Ronald C. W.
Kong, Alice P. S.
Chow, Francis C. C.
Chan, Juliana C. N.
Funding for this research was provided by:
Sugardown Company Limited
Article History
Received: 20 December 2017
Accepted: 21 August 2018
First Online: 31 August 2018
Ethics approval and consent to participate
: The study was approved by the Joint CUHK – New Territories East Cluster Clinical Research Ethics Committee (reference number 2014.426). The study was conducted in accordance to the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines for Good Clinical Practice. All subjects provided written informed consent to participate in the study.
: Not applicable.
: Andrea O.Y, Luk is a member of advisory boards for Astra Zeneca and Amgen, and has previously received research grants from Sanofi, Boehringer Ingelheim and Merck. Juliana C.N. Chan is a member of advisory boards, speaker bureaus and steering committees of multinational studies sponsored by companies including Bayer, Merck, Pfizer, Sanofi, Astra Zeneca, Lilly and Novo-Nordisk with consultancy fees which have been donated to the Chinese University of Hong Kong for supporting education and research in diabetes. Carl W. Rausch is the Chairman and Chief Executive Officer of Boston Therapeutics Inc., and Boston Therapeutics Inc. is involved in the development of BTI320. The remaining authors have no competing interests to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.